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Ankylosing spondylitis (AS) is a common inflammatory arthritis predominantly affecting the axial skeleton. Sus-
ceptibility to the disease is thought to be oligogenic. To identify the genes involved, we have performed a genomewide
scan in 185 families containing 255 affected sibling pairs. Two-point and multipoint nonparametric linkage analysis
was performed. Regions were identified showing “suggestive” or stronger linkage with the disease on chromosomes
1p, 2q, 6p, 9q, 10q, 16q, and 19q. The MHC locus was identified as encoding the greatest component of suscep-
tibility, with an overall LOD score of 15.6. The strongest non-MHC linkage lies on chromosome 16q (overall LOD
score 4.7). These results strongly support the presence of non-MHC genetic-susceptibility factors in AS and point
to their likely locations.
Introduction
Ankylosing spondylitis (AS) is the second-most-common
cause of inflammatory arthritis worldwide, with a prev-
alence of 1/1,000–3/1,000 in white populations (Calin
1998). It is characterized by inflammation in the spine
and sacroiliac joints, causing initial bone and joint ero-
sion and subsequent ankylosis. Arthritis affecting pe-
ripheral joints, particularly the hips, occurs in 40% of
cases, and inflammation may also involve extraarticular
sites such as the uvea, tendon insertions, aorta, lungs,
and kidneys. Genetic factors were implicated in the eti-
ology of the disease long ago, with the demonstration
of high disease familiality (de Blecourt et al. 1961). The
sibling recurrence-risk ratio is 82 (Brown et al. 2000b),
and heritability, assessed by twin studies, is 190%
(Brown et al. 1997). The recognition of the association
of B27 with AS confirmed the importance of heritable
factors in the disease (Brewerton et al. 1973; Schlosstein
et al. 1973) and remains one of the strongest disease
associations of any inflammatory human disease. In
most populations that have been studied, the prevalence
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of AS is strongly correlated with the prevalence of the
main disease-susceptibility gene, HLA-B27 (B27). Only
a few families have been reported in which AS segregates
independently from B27 (van der Linden et al. 1975;
Gladman et al. 1986; Deshayes et al. 1987; Woodrow
1988; Brown et al. 1996; Said-Nahal et al. 2000) and
only rare cases of familial B27-negative AS have been
reported (Rubin et al. 1994; Skomsvoll et al. 1995),
suggesting that B27 is almost essential for the inheritance
of AS within families. However, only 1%–5% of B27-
positive individuals develop AS, and there is increasing
evidence to suggest that other genes must also be in-
volved. B27-positive relatives of AS patients have a re-
currence risk of the disease that is 5.6–16 times greater
than that of B27-positive individuals in the population
at large, implying the presence of non-B27 shared fa-
milial risk factors (Calin et al. 1983; van der Linden et
al. 1983). Recurrence-risk modeling in AS rejects single-
gene and polygenic models. Oligogenic models with be-
tween three and nine genes operating in addition to B27
fit the observed pattern of recurrence risks in relatives
of patients with AS (Brown et al. 2000b). A major non-
B27 contribution to susceptibility to AS is suggested by
the greater concordance rate in MZ twins (63%) than
in B27-positive DZ twin pairs (23%) (Brown et al.
1997).
A preliminary whole-genome screen in 105 affected-
sibling-pair families with AS demonstrated strong link-
age to the MHC locus (LOD 8.1) but also identified
several other regions with moderate evidence of linkage
(Brown et al. 1998). Six regions lying on chromosomes
2p, 2q, 3p, 10q, 11p, and 16q achieved LOD scores
11.0, with the peak non-MHC linkage occurring on
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Table 1
Summary of Families Included in Genome Screen
NO. OF
SCREEN
1 2 1 and 2
Families:
Overall 99 86 185
With two affected sibs 87 69 156
With three affected sibs 7 9 16
With four affected sibs 2 1 3
With five affected sibs … 1 1
With sibling pairs in two generations 2 5 7
With a sibling trio in one generation
and a sibling pair in another … 1 1
With sibling trios in two generations 1 … 1
With other first- or second-degree
relatives 21 18 39
With both parents 50 29 79
With one parent 22 29 51
With no parents 27 28 55
Sibling pairs overall 130 125 255
Affected individuals 235 210 445
Unaffected individuals 187 186 373
chromosome 16q (LOD 2.6). Candidate-gene studies
have also implicated the gene cytochrome P450 2D6,
lying on chromosome 22q13.1, in susceptibility to AS
(Beyeler et al. 1996; Brown et al. 2000a) and suggest
the involvement of more than one MHC gene (Hohler
et al. 1998; Laval et al. 2000).
Since this preliminary study, we have continued to
recruit additional families (screen 2) and have reinves-
tigated our initial families (screen 1) with a denser
marker map. The results of these screens have been an-
alyzed both separately and as a combined cohort con-
sisting of 185 families containing 255 affected sibling
pairs (see table 1). Results of the X-chromosome map-
ping have been presented elsewhere (Hoyle et al. 2000).
Subjects and Methods
Families with AS
This project was approved by the Central Oxford Re-
search Ethics Committee (approval CM95.061) and the
University of Toronto Ethics Committee. AS was defined
according to the modified New York diagnostic criteria
(van der Linden et al. 1984). All patients had been seen
by a qualified rheumatologist, and the diagnosis of AS
had been confirmed. To further confirm the diagnosis,
all cases either were examined or were interviewed by
telephone by one of us (L.B., M.A.B., or L.R.). In pa-
tients with atypical histories or for whom radiographs
had not been performed previously, pelvic and lumbos-
acral spine radiographs were obtained, and attending
physicians were contacted to confirm the diagnosis. All
family members were typed for HLA-B27 (see below),
and all the affected individuals were B27-positive. All
family members were of white descent. Among partici-
pants affected with AS, the mean age at time of recruit-
ment was 46 years (range 16–86 years), 63%were male,
and 44% reported having had iritis, 16% psoriasis, and
9% inflammatory bowel disease.
Two cohorts of families were recruited (screens 1 and
2—see table 1 for family details). Six families included
in our initial publication have been excluded from the
current study because of changes of diagnosis or pater-
nity (outlined below). Although both screens have sim-
ilar numbers of affected sibling pairs, there are signifi-
cant differences between the two cohorts. Screen 2 has
fewer families (86) than screen 1 (99) and fewer affected
individuals (210) than screen 1 (235). Blood samples
were available from a higher proportion of parents in
screen 1 families (62% of all parents) than of parents
in screen 2 families (51% of all parents). Thus, it is likely
that the power to detect linkage was higher for the screen
1 families than the screen 2 families.
Genotyping
All individuals were typed for HLA-B27 by PCR-SSP
(Brown et al. 1996). Screen 1 families were genotyped
for 505 autosomal microsatellite markers, including 259
markers from the Medical Research Council (United
Kingdom) set (Reed et al. 1994), 5 markers lying within
the MHC locus (62A, 82-1, 82-2, T2, and D3A) (Hsieh
et al. 1997), and 241 additional markers from the Ap-
plied Biosystems Prism Linkage Mapping Set Version 2
(LMSv2) marker set (PE Biosystems). Screen 2 families
were genotyped for 367 markers from the LMSv2
marker set (not including markers excluded by error-
checking procedures). The markers were amplified by
methods reported elsewhere (Brown et al. 1998), pooled
in sets of 15–20 markers, and products were separated
by electrophoresis in 6% polyacrylamide gels using ABI
373 semiautomated sequencers. Products were sized us-
ing the program GENESCAN 672, version 1.1 (PE Bios-
ystems), and genotypes were assigned semiautomatically
using the program GENOTYPER, version 1.1 (PE
Biosystems).
Statistical Analysis
To minimize data errors, extensive checking proce-
dures were employed. Mendelian inheritance of markers
was checked manually within GENOTYPER, and the
program GAS, version 2.0 (A. Young, unpublished), was
used to convert the size data into discrete allele numbers.
Consistency of allele assignment was ensured by use of
a control sample on each gel and by comparison of allele
distributions between screens. The program PED-
CHECK (O’Connell and Weeks 1998) then was used to
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screen all data for previously undetected inconsistencies
of Mendelian inheritance. The relationship between ped-
igree members was then examined, using the results of
190 markers, by means of the program SIBERR (Ehm
et al. 1998). This program identifies misspecification of
probable MZ twins, half-siblings, and unrelated indi-
viduals as full sibling pairs by comparison of the number
of alleles shared IBD at unlinked loci with null hypoth-
esis expectations. One previously unrecognizedMZ twin
pair was identified by this program and was removed
from the analysis. This pair was identical at 181 of 182
alleles checked (0.5% genotyping-error rate). Excess re-
combination events between markers, a finding sugges-
tive of genotyping error, was screened for, by calculation
of recombination distances, using the program SIM-
WALK2 (Sobel and Lange 1996). Of the 527 markers
used, 3 were removed from the screens as a result of this
analysis. Finally, non-Mendelian errors were investi-
gated further using the program SIBMED (Douglas et
al. 2000). SIBMED identifies likely genotyping errors
and marker mutations by calculating the posterior prob-
ability of an error for each sibling-pair–marker combi-
nation. The prior probability of genotype error was set
at 1%, and genotypes of sibling-pair–marker combi-
nations with a posterior probability of error of 150%
were checked. Among the 614,929 genotypes scored, 51
genotype errors (0.008%) were identified by this pro-
gram and were removed from the analysis.
Allele frequencies were calculated, from all scored
genotypes, by means of the program DOWNFREQ (J.
Terwilliger). Marker positions were obtained from pub-
lic databases (either the Whitehead Institute for Bio-
medical Research database or GeneMap’99).
Multipoint analysis theoretically is more accurate in
identifying the position of maximum linkage and has
greater power to identify linkage but is susceptible to
biases that are less important in two-point analysis.Mul-
tipoint analysis depends critically on the correct marker
order and intermarker distances. Genotyping errors in
two-point analysis affect only the marker involved,
whereas, in multipoint analysis, they can also affect
surrounding markers. Therefore, both analyses are
presented.
Two-point nonparametric affected-sibling-pair link-
age analysis was performed using the program ANA-
LYZE (Satsangi et al. 1996). Multipoint nonparametric
linkage analysis was performed using the ALL statistic
of the program GENEHUNTER-PLUS (Kong et al.
1997). IBD sharing by affected sibling pairs was deter-
mined using GENEHUNTER, version 2.0 (Pratt et al.
2000), and confidence intervals for locus-specific l
values were determined by methods reported elsewhere
(Cordell and Olson 1997). The contribution of each lo-
cus to the overall sibling recurrence risk was calculated
assuming a sibling recurrence-risk ratio of 82 (Brown et
al. 2000b) and either additive (Norman et al. 1998) or
multiplicative (Risch 1987) interaction between loci.
“Suggestive” and “significant” linkage are defined, ac-
cording to published recommendations for affected-sib-
ling-pair nonparametric analysis, as LOD  2.2 and
LOD  3.6, respectively (Lander and Kruglyak 1995).
Results
Two-point results for markers achieving LOD scores of
1.0 in screens 1 and 2 and the combined results are listed
in table 2. Twenty-eight markers from 14 regions
achieved LOD scores of 1.0 in screen 1. Among these,
three markers (D6S276, D10S185, and D16S422) from
three regions achieved LOD scores of 1.0 in screen 2.
Strong linkage with the MHC locus in this set was ob-
served, with a peak LOD score of 6.9. Outside of the
MHC locus, “significant” linkage was observed with
marker D9S1826 (LOD 3.9). “Suggestive” linkage was
observed for markers D10S597 (LOD 2.4) andD16S289
(LOD 2.7). In screen 2, 22 markers from 11 regions
achieved LOD scores of 1.0. Of these, three markers
(D6S276, D10S185, and D16S422) from three regions
achieved linkage with LOD 1.0 in screen 1. Strong link-
age was again observed with the MHC locus (LOD 4.8).
“Significant” linkage was only observed with the mi-
crosatellites in the region of the MHC locus. Outside of
the MHC locus, “suggestive” linkage was observed with
markers D7S519 (LOD 2.6), D19S414 (LOD 2.5), and
D19S420 (LOD 3.58). Considering the combined data
across both screens, 34 markers from 14 regions
achieved LOD scores of 1.0. Five markers from four
regions achieved “suggestive” linkage (markers D1S255
[LOD 2.2], D9S288 [LOD 2.3], D9S1682 [LOD 2.3],
D9S1826 [LOD 2.8], and D16S422 [LOD 3.3]).
The results of the multipoint analysis are given in
figure 1. For most loci, there are only minor differences
between the two-point and multipoint LOD scores, but,
for a small number of loci, quite marked differences
were observed. For the MHC locus, the peak LOD
scores obtained in screen 1, 2, and the combined screen,
respectively, were 7.8, 8.1, and 15.6. The l value for
this locus overall was 5.2 ( , ,z p 0.048 z p 0.50 1
, where is the probability of sharing n al-z p 0.45 z2 n
leles identical by descent). The contribution of theMHC
locus ( , 95% CI 3.0–9.0) to the recurrence-risklp 5.2
ratio in AS is either 37%, under a multiplicative disease
model, or 6.8%, under an additive disease model. Mul-
tipoint analysis demonstrated greater evidence of link-
age on chromosomes 2, 5, and 16 than did two-point
analysis and showed less evidence of linkage on chro-
mosomes 1 and 7. On chromosome 1, the peak mul-
tipoint linkages were at 60 cM from the p telomere,
with LOD scores in screens 1 and 2 and the combined
analysis being 0.6, 1.1, and 1.7, respectively. On chro-
Table 2
Two-Point Linkage Results for Screens 1 and 2 and the Combined Data Set, Using the Program ANALYZE
CHROMOSOME
AND MARKER
DISTANCE FROM P TELOMERE
(cM)
SCREEN 1 SCREEN 2 SCREENS 1 AND 2
LOD P LOD P LOD P
1:
D1S199 47.7 1.2 .01 .0 .41 .5 .07
D1S255 66.6 1.7 .0029 .6 .046 2.2 .0007
D1S197 78.3 1.0 .014 .0 .5 .5 .074
D1S484 173.9 1.0 .016 .4 .083 1.4 .0053
D1S2836 290.1 .6 .045 .7 .032 1.3 .007
2:
D2S391 73.8 1.0 .017 .4 .083 1.3 .0073
D2S337 84.1 1.3 .0079 .1 .23 1.1 .014
D2S160 127.4 1.1 .011 .2 .18 1.1 .011
D2S347 135.7 .7 .034 .4 .076 1.2 .011
D2S335 182.5 1.2 .0083 .0 .5 .5 .069
D2S157 212.6 1.6 .0034 … … 1.6 .0034
3:
D3S1300 79 1.1 .012 .0 .5 .4 .092
D3S1314 218.3 .0 .5 1.4 .0061 .6 .044
5:
D5S400 174.3 .0 .5 1.4 .0056 .6 .044
6:
D6S309 13.6 .0 .5 1.5 .0043 .8 .026
D6S470 17.7 .1 .26 3.1 .000079 2.2 .00066
D6S289 29.55 .8 .028 1.9 .0017 2.5 .00033
D6S422 35.7 .9 .02 2.9 .00012 3.6 .000023
D6S276 44.8 1.8 .0022 4.8 .0000013 6.5 !106
82II 44.95 6.9 !106 … … 6.9 !106
HLADRA 46.05 3.9 .000011 … … 3.9 .000011
D6S291 49.8 1.2 .0097 … … 1.2 .0097
D6S1610 53.9 1.5 .0042 … … 1.5 .0042
D6S257 80 1.0 .015 .7 .033 1.7 .0024
D6S460 90 .6 .045 2.0 .0012 2.4 .00041
7:
D7S519 70.5 .0 .5 2.6 .00025 .6 .045
8:
D8S1784 116.8 .7 .042 .8 .024 1.5 .0043
D8S514 128.9 .5 .068 .6 .054 1.0 .014
9:
D9S288 8.8 1.6 .003 .7 .037 2.3 .00058
D9S286 16.8 .5 .066 1.0 .014 1.5 .0044
D9S161 50.3 .6 .043 .7 .032 1.4 .006
D9S283 93.2 .7 .039 1.2 .01 1.8 .0019
D9S1682 132.9 .5 .068 2.1 .001 2.3 .0006
D9S1826 160.2 3.9 .000013 .0 .33 2.8 .00016
10:
D10S185 123.3 1.0 .016 1.1 .012 2.1 .0009
D10S192 131.2 1.5 .0041 .2 .2 1.1 .011
D10S597 137.6 2.4 .00043 .1 .23 1.8 .0022
D10S190 147.2 1.0 .015 .1 .29 .8 .025
11:
D11S922 3.2 1.1 .014 … … 1.1 .014
D11S935 49.6 1.1 .011 .0 .5 .6 .054
15:
D15S165 20.2 .0 .5 1.6 .003 .4 .078
16:
D16S3068 46.6 1.3 .0068 .0 .5 .0 .39
D16S515 90.2 1.8 .0022 .0 .5 1.1 .014
D16S516 98.3 .8 .028 .4 .095 1.1 .012
D16S422 109.1 1.4 .0049 1.9 .0015 3.3 .000044
D16S289 122.1 2.7 .0002 … … 2.7 .0002
17:
D17S831 6.6 .0 .32 1.2 .0093 1.0 .014
19:
D19S226 41.7 .3 .14 1.2 .009 1.3 .0065
D19S414 53.2 .0 .5 2.5 .00037 .7 .042
D19S220 61.4 .0 .48 1.8 .0021 1.1 .013
D19S420 66 .0 .44 3.58 .000025 2.0 .0012
D19S902 76.2 .4 .096 1.7 .0025 1.9 .0016
D19S571 87.7 .3 .13 1.4 .0058 1.4 .0057
21:
D21S266 49.9 1.1 .011 .4 .092 1.4 .0052
NOTE.—Markers scoring LOD 1.0 in any screen are presented. Results achieving “significant” linkage (LOD 3.6) are indicated in boldface italics, and those
achieving “suggestive” linkage (LOD 2.2 and !3.6) are underlined.
Figure 1 Multipoint results for screens 1 and 2 and the combined data set using the program GENEHUNTER PLUS. Screen 1 results
are given with a dotted line, screen 2 with a dashed and dotted line, and the combined results with an unbroken line.
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mosome 2, the maximum multipoint LOD scores in
screens 1, 2, and the combined analysis were 1.8, 0.8,
and 2.5, respectively, at 132, 125, and 132 cM from
the p telomere, respectively. The magnitude of this locus
is (95% CI 1.3–2.3). On chromosome 5, link-lp 1.7
age with a multipoint LOD score of 2.3 was observed
at 168 cM in screen 2, compared with the two-point
LOD score of 1.4. No significant evidence of linkage
was observed at this locus by multipoint analysis of
screen 1, resulting in a maximum LOD score, in the
combined set, of only 1.2. On chromosome 7, the “sug-
gestive” linkage observed at marker D7S519 in screen
2 was reduced in multipoint analysis to a maximum
LOD score of 0.8. Two separate regions were identified
on chromosome 9, although the region around D9S288
at 8.8 cM showed little support in multipoint analysis,
suggesting that it may be a false-positive finding. The
region around D9S283 showed “suggestive” linkage by
multipoint analysis (maximum LOD score 2.2 at 124
cM), and, by two-point analysis, marker D9S1826 (at
160.2 cM) achieved a LOD score of 2.8 overall. The
locus is of magnitude (95% CI 1.1–2.0). Alp 1.5
region on chromosome 10 was identified with “sugges-
tive” linkage in screen 1 (maximum multipoint LOD
score of 2.6 at 134 cM), and support in screen 2 with
peak multipoint linkage of LOD 0.8 at 109 cM. In the
combined data set, the maximum multipoint linkage
score was LOD 1.9 at 136 cM. The overall magnitude
of this locus is . On chromosome 16, the max-lp 1.2
imummultipoint LOD scores were greater than the two-
point scores, with maximum LOD scores, for screens 1
and 2 and the combined analysis, of 4.1, 1.2, and 4.7,
respectively, at 106 cM, 99 cM, and 101 cM from the
p telomere, respectively. The locus magnitude is lp
(95% CI 1.3–2.4), equivalent to 13% or 2.2% of1.8
the recurrence-risk ratio for polygenic multiplicative or
additive models, respectively. Multipoint analysis of
chromosome 19 showed a broad region of linkage in
screen 1 particularly, with peak multipoint LOD scores
in screens 1 and 2 and the combined data set of 3.1,
0.5, and 2.5, at 59 cM, 65 cM and 65 cM, respectively.
As previously reported, no linkage was observed on
the X chromosome ( ) (Hoyle et al. 2000) byP ! .05
either two-point or multipoint analysis.
Discussion
This study provides strong evidence supporting the ex-
istence of non-MHC genes involved in AS, and points
to their likely location. Regions on chromosomes 1, 2,
6, 9, 10, 16, and 19 were identified that have either
“significant” or “suggestive” linkage (Lander and Krug-
lyak 1995) in either screen or in the combined screens.
The power of each screen to detect linkage to genes
of moderate effect is only moderate. Setting the thresh-
old for detection of LOD  1.0, and assuming all af-
fected sibling pairs have parents available for genotyp-
ing and are all independent, screens 1 and 2 have 80%
power to detect a locus of magnitude andlp 1.9
, respectively (Risch 1990). Under the same as-lp 2.1
sumptions, the study is estimated to have 80% power
overall to detect loci of magnitude . Becauselp 1.6
many parents were missing in both screens and the num-
ber of independent sibling pairs is lower than the total,
the actual power of this study is lower than these es-
timates. However, it is clear that while the study had
good power overall to detect loci with moderate effects,
the power of each screen to replicate findings of the
other screen was not high. Therefore, loci identified in
one screen may not be identified in the other. Despite
this, several regions showed sufficiently strong evidence
of linkage in both screens to be unlikely to be false
positives.
The strong linkage demonstrated in this study with
the MHC locus is further evidence confirming the cen-
tral role of HLA-B27, possibly in combination with
other MHC genes, in susceptibility to AS. The magni-
tude of this locus ( ) is considerably greater thanlp 5.2
that of any other locus identified, which were all of
magnitude , and confirms the central role ofl ! 1.9
genes encoded at this locus in susceptibility to AS. All
affected relative pairs sharing 0 haplotypes identical by
descent at the MHC locus were nonetheless B27-posi-
tive (identical by state), and in no family was AS in-
herited independently of B27. Thus, B27 appears to be
essential to the inheritance of AS within families, but
there is also considerable epidemiological evidence for
the existence of significant non-B27 genetic suscepti-
bility.
The strongest linkage observed outside of the MHC
locus is on chromosome 16q, where maximum linkage
was observed at 101 cM from the p telomere (LOD
4.7), equivalent to a genomewide significance level of
!.005 (Lander and Kruglyak 1995). Both screens
showed significant support for this locus, with screen 1
achieving LOD 4.1 at 106 cM and screen 2 LOD 1.2
at 99 cM, making it quite unlikely that either represents
a chance finding. The region of linkage is very broad,
with the 3-LOD confidence interval extending from 84
to 114 cM, and contains numerous potential candidate
genes. Further refinement of this interval by high-density
association/linkage disequilibrium mapping will be
required to identify the actual genes involved.
Other regions identified as showing at least “sugges-
tive” linkage included loci on chromosomes 1, 2, 9, 10,
and 19. On chromosome 1, marker D1S255 achieved
“suggestive” linkage overall (LOD 2.2) with support in
both screens, but the multipoint linkages were weaker
(LOD 1.7 overall). On chromosome 2, a region was
identified by multipoint analysis, lying 123–130 cM
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from the p telomere. The IL-1/IL-1 RA complex is
encoded in this region, and association studies of the
IL-1 RA gene previously have reported association of
alleles of an IL-1 RA VNTR with AS (McGarry et al.
2000; Van der Paardt et al. 2000). On chromosomes
9q and 10q, there were substantial differences in max-
imum points of linkage for screens 1 and 2. On chro-
mosome 9q, although the maximum points of linkage
by multipoint analysis were similar for screens 1 and 2,
by two-point analysis there were substantial differences.
In screen 1, marker D9S1826 achieved significant link-
age (LOD 3.9; position 160.2 cM), with no support in
screen 2. In screen 2, marker D9S1682, located at 132.9
cM, achieved a LOD score of 2.1 in screen 2, but a
LOD of only 0.5 in screen 1. On chromosome 10, the
peak position of linkage differed in screens 1 and 2 by
25 cM. By two-point analysis, one marker lying in this
region (D10S192, at 131.2 cM) had good support in
both screens, achieving LOD scores of 1.1, 1.0, and 2.1
in screens 1 and 2 and in the combined data set, re-
spectively. It is a well-recognized characteristic of link-
age analyses that the maximum position of linkage may
vary between genome screens (Roberts et al. 1999), and,
therefore, one locus may produce the different point of
maximum linkage results in this region in the two
screens. Further linkage mapping on chromosomes 9
and 10 may help define better the true regions of linkage
in the different data sets. The region on chromosome
19 that achieved “suggestive” linkage in screen 1
(marker D19S420; LOD 3.58) achieved only minor sup-
port in screen 2 (peak multipoint LOD score 0.5), and
further studies will be required to confirm this finding.
Replication of linkages in complex genetic diseases
has often proved unreliable, resulting in confusion as
to which linkages are true- or false-positive findings.
Reasons for this include use of insufficiently stringent
thresholds for identification of loci, genetic heteroge-
neity, and inadequate power of replication studies. To
achieve 80% power to detect a locus of magnitude
in a complex genetic disease (equivalent to thelp 1.8
magnitude of the chromosome 16q locus in this screen),
even at a low significance threshold of LOD 1.0, will
require studying 200 affected sibling pairs (with both
parents available for genotyping, using a 10-cMmarker
map). The low power of linkage studies to replicate
small genetic effects must be considered in comparisons
between the results of future genetic studies and those
presented here.
No other genomewide scans have been reported in
AS, but scans have been completed in both psoriasis
and inflammatory bowel disease, which are clinically
related to AS. AS frequently complicates inflammatory
bowel disease, and subclinical bowel inflammation is
present in the majority of AS cases (Mielants et al.
1991). Strong linkage of chromosome 19 similar to that
observed in our screen 2 was recently identified in a
genomewide screen in inflammatory bowel disease
(Rioux et al. 2000). The two other main IBD linkages
(IBD1, located in the pericentromeric region of chro-
mosome 16, and IBD2, located on chromosome 12)
showed no evidence of linkage with AS in this study.
Genomewide linkage studies in psoriatic skin disease
have identified replicated linkages on chromosomes
1cen-q21, 3q21, 4q, 6p (PSORS1, the MHC region),
17q, 19p13, and 20p (Enlund et al. 1999; Samuelsson
et al. 1999; Lee et al. 2000). Of these regions, we iden-
tified strong linkage at the MHC locus and on chro-
mosome 19, weak linkage in chromosome 1q, and no
linkage on chromosomes 3q21, 4q, and 17q. The peak
linkage in both psoriasis and inflammatory bowel dis-
ease lies on chromosome 19p (Lee et al. 2000; Rioux
et al. 2000), but, as in our own study, the area of linkage
is quite broad, and considerable overlap exists. A ge-
nomewide screen has recently been reported in families
with psoriatic arthritis (Samuelsson et al. 1999). Ar-
thritis in psoriasis is clinically heterogeneous, and only
a proportion of cases suffer from a spondyloarthritis
similar to AS. Nonetheless, there are some overlaps with
the findings presented here. Specifically, regions on chro-
mosomes 1q, 5q, and 15p showed evidence of linkage
to both diseases, adding support to our findings.
The ultimate proof that genes other than HLA-B27
are involved in AS awaits identification of the actual
genes involved. The linkage results presented in this
study represent an important advance in that search.
This study presents strong evidence of the involvement
with AS of genes localized on chromosomes 1p, 2q, 6p,
9q, 10q, 16q, and 19q. Further linkage mapping, po-
sitional candidate, and linkage disequilibrium studies
are under way to define these regions better and to iden-
tify the actual genes involved.
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